These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 23657376)
1. Second oral MS drug wins FDA nod. Sheridan C Nat Biotechnol; 2013 May; 31(5):373. PubMed ID: 23657376 [No Abstract] [Full Text] [Related]
2. Dimethyl fumarate (Tecfidera) for multiple sclerosis. Med Lett Drugs Ther; 2013 Jun; 55(1418):45-7. PubMed ID: 24662841 [No Abstract] [Full Text] [Related]
3. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis. English C; Aloi JJ Clin Ther; 2015 Apr; 37(4):691-715. PubMed ID: 25846320 [TBL] [Abstract][Full Text] [Related]
4. Diroximel fumarate to treat multiple sclerosis. Wang Y; Bhargava P Drugs Today (Barc); 2020 Jul; 56(7):431-437. PubMed ID: 32648853 [TBL] [Abstract][Full Text] [Related]
5. Dimethyl fumarate (Tecfidera): a new oral agent for multiple sclerosis. Venci JV; Gandhi MA Ann Pharmacother; 2013 Dec; 47(12):1697-702. PubMed ID: 24259625 [TBL] [Abstract][Full Text] [Related]
6. Response to comment on "Dimethyl fumarate (tecfidera): a new oral agent for multiple sclerosis". Venci J; Gandhi MA Ann Pharmacother; 2014 Nov; 48(11):1537. PubMed ID: 25301830 [No Abstract] [Full Text] [Related]
7. Safety profiles come to fore as more drugs approach MS market. Sheridan C Nat Biotechnol; 2012 Jan; 30(1):6-8. PubMed ID: 22231075 [No Abstract] [Full Text] [Related]
8. Escalating MS drug costs in the US: Puzzling, troubling, and suspicious. Murray TJ; Brown MG Neurology; 2015 May; 84(21):2105-6. PubMed ID: 25911109 [No Abstract] [Full Text] [Related]
9. Lorcaserin, dimethyl fumarate, and bedaquiline fumarate. Hussar DA; Polyak G J Am Pharm Assoc (2003); 2013; 53(3):328-30, 332, 334. PubMed ID: 23699683 [No Abstract] [Full Text] [Related]
11. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis. Thomas RH; Wakefield RA Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835 [TBL] [Abstract][Full Text] [Related]
12. Cost of disease-modifying therapies for multiple sclerosis. Brown MG Neurology; 2015 May; 84(21):e181-5. PubMed ID: 26009567 [No Abstract] [Full Text] [Related]
13. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail? Rittenhouse BE Neurology; 2015 Nov; 85(19):1727-8. PubMed ID: 26866071 [No Abstract] [Full Text] [Related]
14. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail? Tischner JR Neurology; 2015 Nov; 85(19):1727. PubMed ID: 26553943 [No Abstract] [Full Text] [Related]